Clariane SE (FRA:KO2) Research & Development: €0 Mil (TTM As of Dec. 2025)


FRA:KO2 Clariane SE FRA:KO2
61 GF Score
Price €4.20
GF Value €2.46
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Clariane SE Research & Development?

Clariane SE FRA:KO2 +1.50% 61 Research & Development is €0 Mil as of Dec. 2025. GuruFocus rates FRA:KO2 with a GF Score™ of 61/100 and a GF Value™ of €2.46 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Clariane SE's Research & Development for the six months ended in Dec. 2025 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0 Mil.

Clariane SE  (FRA:KO2) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Clariane SE Research & Development Related Terms

Clariane SE Research & Development Historical Data

* Premium members only.

The historical data trend for Clariane SE's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clariane SE Research & Development Chart

Clariane SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Clariane SE Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:KO2
61GF Score
Clariane SE FRA:KO2
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clariane SE Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Clariane SE (FRA:KO2) has a Research & Development of €0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Clariane SE and its competitors.
Is Clariane SE's Research & Development too high?
Clariane SE's current Research & Development is €0 Mil. Overall, Clariane SE has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's Research & Development compare to HCA and THC?
Clariane SE's Research & Development of €0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Clariane SE and its competitors. Clariane SE's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (FRA:KO2) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.46, compared to a current price of €4.20 — trading 70.8% above its estimated fair value. The current Research & Development is €0 Mil. Clariane SE's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Clariane SE (FRA:KO2), the current Research & Development is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clariane SE (FRA:KO2) Overvalued in 2026?

Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued. The current stock price of €4.20 is trading 70.8% above its estimated GF Value™ of €2.46. GuruFocus considers Clariane SE to be Significantly Overvalued.

Key valuation signals for FRA:KO2:

  • Research & Development: €0 Mil
  • GF Value™: €2.46 vs. price of €4.20 (70.8% above fair value)
  • GF Score™: 61/100 with 9 warning signs

No single metric tells the full story. See the FRA:KO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clariane SE Business Description

Address 21-25, Rue Balzac, Paris, FRA, 75008
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
61GF Score

Get the complete analysis for FRA:KO2

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.20
Price
€2.46
GF Value